Astria Therapeutics, Inc.
ATXSNASDAQHealthcare
$12.58
+$0.00(+0.00%)
Market Cap$718127262
P/E Ratio—
52W High$13.29
52W Low$3.555
Astria Therapeutics, Inc. (ATXS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ATXS · earnings · updated Jun 8, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 12, 2025EPS Actual
-$0.55
Est. -$0.41 · -34.1%
Revenue
$0.00B
Est. $0.01B · -93.4%
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 12, 2025
After Market Close
▼ Miss EPS▼ Miss Revenue
ATXS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q4 FY2025 | Nov 12, 2025 | -$0.41 | -$0.55 | -34.1% | $0.00B | $0.01B | -93.4% |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.61 | -$0.57 | +6.6% | — | $0.01B | — |
| ▼ Q2 FY2025 | May 13, 2025 | -$0.48 | -$0.58 | -20.8% | — | — | — |
| ▲ Q1 FY2025 | Mar 11, 2025 | -$0.45 | -$0.44 | +2.2% | — | — | — |
| — Q4 FY2024 | Nov 13, 2024 | -$0.42 | -$0.42 | +0.0% | — | — | — |
| ▼ Q3 FY2024 | Aug 12, 2024 | -$0.37 | -$0.43 | -16.2% | — | — | — |
| ▼ Q2 FY2024 | May 9, 2024 | -$0.35 | -$0.38 | -8.6% | — | — | — |
| ▼ Q1 FY2024 | Mar 4, 2024 | -$0.69 | -$0.86 | -24.6% | — | — | — |
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
-$0.55
EPS Est.
-$0.41
EPS Surpr.
-34.1%
Revenue
$0.00B
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.57
EPS Est.
-$0.61
EPS Surpr.
+6.6%
Revenue
—
Q2 FY2025
May 13, 2025Miss
EPS Actual
-$0.58
EPS Est.
-$0.48
EPS Surpr.
-20.8%
Revenue
—
Q1 FY2025
Mar 11, 2025Beat
EPS Actual
-$0.44
EPS Est.
-$0.45
EPS Surpr.
+2.2%
Revenue
—
Q4 FY2024
Nov 13, 2024
EPS Actual
-$0.42
EPS Est.
-$0.42
EPS Surpr.
+0.0%
Revenue
—
Q3 FY2024
Aug 12, 2024Miss
EPS Actual
-$0.43
EPS Est.
-$0.37
EPS Surpr.
-16.2%
Revenue
—
Q2 FY2024
May 9, 2024Miss
EPS Actual
-$0.38
EPS Est.
-$0.35
EPS Surpr.
-8.6%
Revenue
—
Q1 FY2024
Mar 4, 2024Miss
EPS Actual
-$0.86
EPS Est.
-$0.69
EPS Surpr.
-24.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.73 | $-0.73 | $-0.73 | 1 |
| Q3 FY2026 | $-0.70 | $-0.70 | $-0.70 | 1 |
| Q2 FY2026 | $-0.67 | $-0.67 | $-0.67 | 1 |
| Q1 FY2026 | $-0.65 | $-0.65 | $-0.65 | 1 |
| Q4 FY2025 | $-0.46 | $-0.46 | $-0.46 | 1 |
| Q3 FY2025 | $-0.63 | $-0.39 | $-0.27 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q4 FY2025 | Nov 12, 2025 | -34.1% | $12.51 | $12.55 | +0.32% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +6.6% | $6.68 | $6.65 | -0.45% |
| ▼ Q2 FY2025 | May 13, 2025 | -20.8% | $4.37 | $3.90 | -10.76% |
| ▲ Q1 FY2025 | Mar 11, 2025 | +2.2% | $5.82 | $6.47 | +11.17% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +0.0% | $11.16 | $10.61 | -4.93% |
| ▼ Q3 FY2024 | Aug 12, 2024 | -16.2% | $9.46 | $9.76 | +3.17% |
| ▼ Q2 FY2024 | May 9, 2024 | -8.6% | $9.57 | $10.17 | +6.27% |
| ▼ Q1 FY2024 | Mar 4, 2024 | -24.6% | $14.98 | $14.26 | -4.81% |
Q4 FY2025+0.32%
Report Date
Nov 12, 2025
EPS Beat/Miss
-34.1%
Price Before
$12.51
Price After
$12.55
Q3 FY2025-0.45%
Report Date
Aug 12, 2025
EPS Beat/Miss
+6.6%
Price Before
$6.68
Price After
$6.65
Q2 FY2025-10.76%
Report Date
May 13, 2025
EPS Beat/Miss
-20.8%
Price Before
$4.37
Price After
$3.90
Q1 FY2025+11.17%
Report Date
Mar 11, 2025
EPS Beat/Miss
+2.2%
Price Before
$5.82
Price After
$6.47
Q4 FY2024-4.93%
Report Date
Nov 13, 2024
EPS Beat/Miss
+0.0%
Price Before
$11.16
Price After
$10.61
Q3 FY2024+3.17%
Report Date
Aug 12, 2024
EPS Beat/Miss
-16.2%
Price Before
$9.46
Price After
$9.76
Q2 FY2024+6.27%
Report Date
May 9, 2024
EPS Beat/Miss
-8.6%
Price Before
$9.57
Price After
$10.17
Q1 FY2024-4.81%
Report Date
Mar 4, 2024
EPS Beat/Miss
-24.6%
Price Before
$14.98
Price After
$14.26
Avg Beat Reaction+1.93%
Avg Miss Reaction-1.16%
Beat Rate3 / 8 quarters
Largest Move+11.17% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ATXS ends December
Astria Therapeutics, Inc. (ATXS) most recently reported earnings on November 12, 2025 for Q4 FY2025, posting EPS of $-0.55 — missing the analyst consensus of $-0.41 by -34.1%. The next ATXS earnings date is expected around September 1, 2026.
Each quarter, investors track ATXS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ATXS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ATXS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ATXS earnings · 5 questionsAstria Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. ATXS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ATXS historically reports after market close (AMC).
ATXS earnings datewhen is ATXS earningsATXS next earnings datewhen does ATXS report earningsATXS earnings calendar
▸ Source: FMP · Astria Therapeutics, Inc. SEC filings · US GAAP · Astria Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026